

Author Index
Volume 48
July—December 1993

- Abas, N., 71
 Acosta, A. A., 277
 Ajossa, S., 445
 Affandi, B., 481
 Amla, S., 150
 Anand, R.J.K., 453
 Ansari, S., 367
 Arce, X.E., 23
 Artújo, M.J., 29
 Au, C.L., 481
 Back, D.J., 377
 Bahamondes, L., 23
 Bardin, C.W., 403
 Batar, I., 349
 Bateman, L., 229
 Basdevant, A., 193
 Baumann, A., 303
 Berta, L., 47
 Bhargava, A.S., 576
 Brännström, M., 393
 Brody, S.A., 37
 Cachrimanidou, A-C, 205
 Castro, S., 23
 Chi, I-c, 81
 Chowdhury, S.R., 178
 Chwalisz, K., 57
 Clark, G.F., 277
 Conard, J., 190
 Cornin, L.M., 229
 Cox, C.A., 229
 Cramer, G.M.U., 494
 Creatsas, G., 349
 Creinin, M.D., 339, 519
 Croxatto, H.B., 548
 Crook, D., 217
 Crosby, U.D., 359
 Darney, P.D., 323, 339
 Degrelle, H., 193
 Diaz, J., 23
 Diaz, M., 23
 Dibbelt, L., 303
 Dildy, G.A., 37
 Dunson, T.R., 109
 Ehn, B.E., 157
 Elger, W., 57
 Faúndes, A., 29
 Fazzari, A., 47
 Felton, C., 217
 Ferreira, A.E., 29
 Fotherby, K., 133
 Fortunati, N., 47
 Frairia, R., 47
 Frank, M.L., 229
 Freihube, G., 576
 Fruzzetti, F., 445
 Gaidano, G., 47
 Ganguly, N.K., 150
 Garg, S., 591
 Gluck, K.L., 359
 Godsland, I.F., 217
 Guerriero, S., 445
 Guha, S.K., 367
 Günzel, P., 576
 Gupta, I., 150
 Guyene, T-T, 193
 Guy-Grand, B., 193
 Hadisaputra, H., 481
 Heartwell, S.F., 359
 He, C-h, 133
 Heikinheimo, O., 548
 Hellberg, D., 205
 Hinduja, I.N., 57
 Hodgen, G.D., 277
 Hümpel, M., 377
 Indian Council of Medical Research Task
 Force on Hormonal Contraception, 120
 Ishwad, P.C., 57
 Israngkura, B., 109
 Johnson, J.A., 71
 Jonasson, K., 471
 Jütting, G., 303, 557
 Katkam, R.R., 57
 Kamboj, V.P., 178, 597
 Kanwar, U., 453
 Kausalya, S., 150
 Kulshreshtha, D.K., 178
 Knuppen, R., 303
 Koivunen, D.G., 71

Author Index
Volume 48
July—December 1993

- Abas, N., 71
 Acosta, A. A., 277
 Ajossa, S., 445
 Affandi, B., 481
 Amla, S., 150
 Anand, R.J.K., 453
 Ansari, S., 367
 Arce, X.E., 23
 Artújo, M.J., 29
 Au, C.L., 481
 Back, D.J., 377
 Bahamondes, L., 23
 Bardin, C.W., 403
 Batar, I., 349
 Bateman, L., 229
 Basdevant, A., 193
 Baumann, A., 303
 Berta, L., 47
 Bhargava, A.S., 576
 Brännström, M., 393
 Brody, S.A., 37
 Cachrimanidou, A-C, 205
 Castro, S., 23
 Chi, I-c, 81
 Chowdhury, S.R., 178
 Chwalisz, K., 57
 Clark, G.F., 277
 Conard, J., 190
 Cornin, L.M., 229
 Cox, C.A., 229
 Cramer, G.M.U., 494
 Creatsas, G., 349
 Creinin, M.D., 339, 519
 Croxatto, H.B., 548
 Crook, D., 217
 Crosby, U.D., 359
 Darney, P.D., 323, 339
 Degrelle, H., 193
 Diaz, J., 23
 Diaz, M., 23
 Dibbelt, L., 303
 Dildy, G.A., 37
 Dunson, T.R., 109
 Ehn, B.E., 157
 Elger, W., 57
 Faúndes, A., 29
 Fazzari, A., 47
 Felton, C., 217
 Ferreira, A.E., 29
 Fotherby, K., 133
 Fortunati, N., 47
 Frairia, R., 47
 Frank, M.L., 229
 Freihube, G., 576
 Fruzzetti, F., 445
 Gaidano, G., 47
 Ganguly, N.K., 150
 Garg, S., 591
 Gluck, K.L., 359
 Godsland, I.F., 217
 Guerriero, S., 445
 Guha, S.K., 367
 Günzel, P., 576
 Gupta, I., 150
 Guyene, T-T, 193
 Guy-Grand, B., 193
 Hadisaputra, H., 481
 Heartwell, S.F., 359
 He, C-h, 133
 Heikinheimo, O., 548
 Hellberg, D., 205
 Hinduja, I.N., 57
 Hodgen, G.D., 277
 Hümpel, M., 377
 Indian Council of Medical Research Task
 Force on Hormonal Contraception, 120
 Ishwad, P.C., 57
 Israngkura, B., 109
 Johnson, J.A., 71
 Jonasson, K., 471
 Jütting, G., 303, 557
 Katkam, R.R., 57
 Kamboj, V.P., 178, 597
 Kanwar, U., 453
 Kausalya, S., 150
 Kulshreshtha, D.K., 178
 Knuppen, R., 303
 Koivunen, D.G., 71

Author Index

- Koul, V., 367
Koumantakis, K., 349
Kuhn, W., 303, 377, 557, 576
Kumar, S., 367
Lachnit, U., 291
Lapousterle, C., 193
Larsson, G., 471
Lau, O.W.K., 267
Leelapattana, B., 109
Lehman, R., 576
Lehnert, J., 291
Li, S., 255
Liljestrand, J., 157
Lindstedt, G., 471
Liu, X., 255
Louton, T., 377
Luo, H., 245
McLaurin, V.L., 109
Mahony, M.C., 277
Mais, V., 445
Maturana, X., 548
Mayer, M., 193
Melis, G.B., 445
Mukherjee, R., 109
Neto, A.M.P., 23
Milsom, I., 471
Nilsson, S., 205
Nóe, G., 548
Oehninger, S., 277
Olsson, S-E, 205
Paoletti, A.M., 445
Parewijck, W., 349
Pelissier, C., 193
Perez-Palacios, G., 109
Poindexter, A.N. III, 37, 229
Praptohardjo, U., 526
Prasertwitayakij, W., 537
Prouder, A.J., 217
Pruithithada, N., 537
Puri, C.P., 57
Rafferty, J., 377
Regina, C.H., 29
Reidenberg, M.M., 513
Rogers, P.A.W., 481
Rugpao, A., 537
Rybo, G., 471
Salek, A.A., 109
Salvatierra, A., 548
Sanyal, S.N., 453
Schwarz, B.E., 359
Setty, B.S., 597
Shi, Y-e, 133
Sidhu, M., 217
Sikström, B., 205
Singh, G., 367
Singh, M.M., 178, 597
Sivin, I., 1
Snabes, M.C., 37
Spitz, I.M., 403
Sreenivasulu, S., 597
Staks, T., 557
Stevenson, J.C., 217
Taluja, V., 591
Talwar, G.P., 591
Tang, G.W.K., 267
Tauber, P.F., 494
Teng, C.S., 168
Thiery, M., 349
Tovanabutra, S., 537
Upadhyay, S.N., 591
Van der Pas, H., 349
Van Look, P.F.A., 133
Van Kets, H., 349
Waldenström, U., 205
Weber-Diehl, F., 291
Wibowo, S., 526
Wonodirekso, S., 481
Worthington, M., 217
Wu, D., 513
Xu, Jijj-q, 133
Xu, R., 245
Ye, Z-h, 133
Yin, M., 245
Yip, P., 267
Yutaboot, Y., 537
Zamah, N.M., 377
Zaneveld, L.J.D., 494
Zhang, G-q, 133
Zhang, J., 13
Zhu, P., 245

Subject Index
Volume 48
July—December 1993

- Abortifacient agents, RU 486 + ONO 802, 267
- Acceptability,
 NORPLANT®, 229
 NORPLANT II, 120¹
 RU 486 + ONO 802, 267
- Active oxygen species, level in Cu IUD users, 150
- Adolescents, performance of T-Cu 200B, 23
- Anchored IUD, CuFix, 349
- Antigestagenic activity, *Ixora finlaysoniana* (rat), 178
- Antiprogesterin, ZK 98.299, 57
- Bioavailability, ST 1435, 548
- Biological effects, RU 486, 403
- Bleeding/pain removal, copper T IUDs, 13
- Blood coagulation, effect of norethisterone acetate (monkey), 576
- Body hair growth, hormonal evaluation, 17
- Bone metabolism, ethinyl estradiol + desogestrel, 445
- Breakage rate, condoms, 537
- Calcium channel blocker, effect on spermatozoal functions, 453
- Carbohydrate metabolism, ethinyl estradiol + desogestrel, 217
- CDRI-85/287, nonsteroidal antiestrogen, 597
- Clinical uses, RU 486, 403
- Condom breakage, 537
- Condom use, failure, 537
- Consistent findings, IUD study, 81
- Continuous use, diaphragm, 29
- Contraceptive efficacy, Praneem polyherbal cream (rabbit, monkey), 591
- Controversial issues, IUD studies, 81
- Copper IUD, performance in adolescents, 23
- Copper IUD users, active oxygen species level, 150
- Copper T IUDs, 13
- Cu-T 220, 245
- CuFix IUD, 349
- Cyproterone acetate, pharmacokinetics, 557
- Dalkon Shield, 1
- Diaphragm, 29
- Discontinuation rates, NORPLANT II, 120
- Effectiveness, diaphragm, 29
- Efficacy, ethinyl estradiol + desogestrel, 323
- Endometrial epithelial cells, effect of NORPLANT, 481
- Endometrium,
 effect of IUDs, 245
 effect of ZK 98.299 (monkey), 57
- Ethinyl estradiol, pharmacokinetics, 303, 377, 557
- Ethinyl estradiol + cyproterone acetate, 557
- Ethinyl estradiol + desogestrel, 193, 205, 217, 323, 445
- Ethinyl estradiol + gestodene, 291, 303
- Ethinyl estradiol + levonorgestrel, 377
- Ethinyl estradiol + norethindrone, 291
- Ethinyl estradiol + norethindrone acetate, 109
- Ethinyl estradiol + norgestrel, 109
- Experiences, legal sterilization, 157
- Fucoidin, effect on spermatozoa, 177
- Gestodene, pharmacokinetics, 303
- Gossypol,
 effect of potassium deficiency (rat), 513
 effect on spermatoocytes (rat), 168
- Hemostatic effects, ethinyl estradiol + desogestrel, 193
- Hormonal evaluation, idiopathic hypertrichosis, 47
- Hypertension, mestranol-induced (rat), 71
- Hypertrichosis, hormonal evaluation, 47
- Hypothalamic-pituitary-ovarian axis, effect of norethindrone, 37
- Implantation, effect of CDRI-85/287 (rat), 597
- Injectable contraceptive, norethindrone microspheres, 37
- Injectable male contraceptive, 367
- Insufficiently addressed issues, IUD studies, 81

¹NORPLANT is a registered trademark of the Population Council, Inc.

- Intrauterine device (IUD),
 copper, 150
 copper T, 13
 Cu-T 220, 245
 CuFix, 349
 Dalkon Shield, 1
 effect on uterine fluid, 494
 generally consistent findings, 81
 insufficiently addressed issues, 81
 levonorgestrel-releasing, 245
 MLCu-250, 471
 stainless ring SS-type, 245
 still-controversial issues, 81
 T-Cu 200B, 23
 Iron status, Multiload IUD, 471
 IUD studies, review, 81
Ixora finlaysoniana, antigestagenic activity (rat), 178
 Levonorgestrel, subdermal implants, 120, 229, 359, 481
 Levonorgestrel-releasing IUD, 245
 Lipid metabolism,
 ethinyl estradiol + desogestrel, 217
 Norethisterone acetate (monkey), 576
 Long-interval treatment regimen, ethinyl-
 oestradiol + desogestrel, 205
 Male contraceptive, injectable styrene maleic
 anhydride, 367
 Male sterilization, vasectomy techniques,
 255
 Mast cells in endometrium, effect of IUDs,
 245
 Mechanism of action, RU 486, 403
 Medical abortion,
 methotrexate, 519
 methotrexate + misoprostol, 339
 Menstrual blood loss, Multiload IUD, 471
 Mestranol-induced hypertension (rat), 71
 Meta-analysis, Dalkon Shield, 1
 Metabolic effects, ethinyl estradiol + deso-
 gestrel, 193
 Methotrexate, early abortion, 519
 Methotrexate + misoprostol abortion, 339
 Mifepristone (RU 486)
 MLCu-250, 471
 MLCu-375, 471
 Nonsteroidal antiestrogen, CDRI-85/287, 597
 Nestorone^{TM,2} (ST 1435), 548
 Nifedipine, effect on spermatozoal functions,
 453
 No-scalpel vasectomy, 255
 Norethisterone acetate, 576
 Norethindrone microspheres, 37
 NORPLANT, 229, 359, 481, 526
 NORPLANT II, 120
 OC (oral contraceptive)
 Onapristone (ZK 98.299), 57
 Oral contraceptive (OC),
 ethinyl estradiol + cyproterone, 557
 ethinyl estradiol + desogestrel, 193, 205,
 217, 323, 445
 ethinyl estradiol + gestodene, 291, 303
 ethinyl estradiol + levonorgestrel, 377
 ethinyl estradiol + norethindrone, 291
 ethinyl estradiol + norethindrone acetate,
 109
 ethinyl estradiol + norgestrel, 109
 OC, norethisterone acetate, 576
 Ovulation,
 effect of RU 486 (rat), 393
 effect of ZK 98.299 (monkey), 57
 Pelvic infection, Dalkon Shield, 1
 Performance, T-Cu 200B in adolescents, 23
 Pharmacokinetics,
 cyproterone acetate, 557
 ethinyl estradiol, 303, 377, 557
 gestodene, 303
 RU 486, 133
 ST 1435, 548
 Pharmacology, RU 486, 403
 Polyherbal cream, spermicidal formulation,
 591
 Postpartum insertion, CuFix, 349
 Potassium deficiency, effect of gossypol (rat),
 513
 Praneem polyherbal cream, spermicide, 591
 Pregnancy complications, Dalkon Shield, 1
 Prostaglandin analogue, misoprostol, 339

²NestoroneTM is the Population Council trademark for 16-methylene-17- α -acetoxy-19 norprogesterone, previously known as ST 1435.

Contraception 1993;48, December

